Skip to main content
News & Press Releases

Imagin Medical Opens Enrollment for Research Study

By 29 November 2017August 11th, 2022No Comments

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer. 

Vancouver, B.C. and Boston, MA, November 29, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today the first in-human Research Study using the i/Blue Imaging System is open for enrollment and recruitment has begun at the University of Rochester Medical Center. 

The primary purpose of the study entitled Near Infrared Fluorescence Imaging for Bladder Cancer Detection, is to determine the minimal dwell time needed for adequate detection of cancerous cells using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF). Based on previous bench-testing, Imagin anticipates the study will prove that surgeons will be able to “see” the cancerous cells in less than 15 minutes vs. the full hour required by current systems. The study will also evaluate, the patented Simultaneous Acquisition of Differing Images, which will blend the white light and fluorescing images into one, enabling the surgeon, in one step, to identify the precise location of the of the cancerous cells within the bladder. 

It is expected that individuals who participate in this 10-subject study will be recruited principally from the pool of current bladder cancer patients at the Medical Center who meet specific criteria: men and women 18 years or older of any racial or ethnic origin, who are scheduled for a transurethral resection of bladder tumor (TURBT) in the operating room resulting from either a new diagnosis of a potentially malignant bladder mass, or a recurrent tumor. 

Dr. Edward Messing, Chair of Urology at the University of Rochester Medical Center, is the principal investigator of the study, which is registered on the National Institutes of Health (NIH) website It is anticipated the first procedure will be completed within one month, and all ten procedures within four months. The study will be open for an additional nine months for subject follow-up. 

“We’re very excited,” said Imagin’s President and CEO, Jim Hutchens. “This is a major step toward improving bladder cancer detection for those whose lives are affected by this disease.” {00858280;1} 

About Imagin Medical 

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at 

For further information, contact: 

Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: [email protected] 

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.